We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Multimarker Testing Procedure Developed for Rapid DOA Screening

By LabMedica International staff writers
Posted on 03 Dec 2009
A multimarker drugs-of-abuse (DOA) testing procedure has been developed for rapid drug screening programs.

DOA biochips permit the analysis of up to 10 drug classes from a single patient sample, providing rapid and accurate testing. More...
The biochip array technology is based on enzyme-linked immunosorbant assay (ELISA) procedures.

The new drugs-of-abuse testing methods were developed Randox Laboratories (Crumlin, UK), a privately owned diagnostic reagent and equipment manufacturing company. The DOA biochips permit the analysis of up to 10 drug classes from a single patient sample, providing rapid and accurate testing.

Each 9 mm x 9 mm biochip comprises up to 25 discrete test regions on which immobilized antibodies specific to each biomarker are contained. Two DTRs are reserved for quality control testing.

The DOA biochip arrays developed by Randox demonstrate good assay performance and correlation with gas chromatography-mass spectrometry (GC/MS), according to the company.

Two DOA biochip arrays, both validated for use with urine and whole blood, are available: DOA array I contains amphetamine, methamphetamine, barbiturates, benzodiazepine 1 and 2, cannabinoids, cocaine metabolite, methadone, opiates, and phencyclidine; DOA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, d-lysergic acid diethylamide (LSD), 3,4-methylenedioxy-N-methylamphetamine (MDMA)-commonly known as ecstasy, methaqualone, oxycodone 1 and 2, and propoxyphene. Creatinine is included on the arrays as a marker of adulteration when testing urine samples.

The use of oral fluid as a sample matrix is validated on DOA array I, and is currently in development for DOA array II.

Three biochip analyzers have been developed and can be employed for the DOA arrays. The fully automated Evidence was designed for high-throughput laboratories and requires as little as seven μL of urine for all 10 drug classes. This rapid testing platform generates 1,088 tests per hour. Once samples are loaded onto the Evidence, the doors are locked and the PC interface is password protected, providing chain-of-custody information.

The semi-automated Evidence Investigator for medium-sized laboratories and the point-of-application Evidence Multistat analyzer, which generates results in 20 minutes, are also available.

Related Links:
Randox Laboratories


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.